AI Summary
At ESTRO 2024, Felipe Couñago presented findings from a study on postoperative hypofractionated radiotherapy for prostate cancer. The study showed good biochemical response, quality of life, and limited toxicity. The non-randomised HYPORT-ES phase 2 trial included 407 patients and delivered 62.5 Gy in 2.5 Gy fractions using advanced radiotherapy techniques. Results focused on acute and late toxicity outcomes.
Speaking on behalf of researchers from 25 Spanish centres, Felipe Couñago (GenesisCare, Madrid, Spain) reported that moderate postoperative hypofractionated radiotherapy for patients with prostate cancer yields a good biochemical response, quality of life, and limited gastrointestinal and genitourinary toxicity. The non-randomised HYPORT-ES phase 2 trial recruited 407 patients and delivered 62·5 Gy in 2·5 Gy fractions via intensity-modulated radiotherapy or image-guided radiotherapy. Primary outcomes were acute and late toxicity.